HIGHLIGHTS
- who: NMO et al. from the Department of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital have published the article: Molecular Sciences, in the Journal: (JOURNAL)
- what: The aim of this review is to summarize the pathogenesis biological basis and new treatment options of these disorders with a particular focus on applications. The results of the trial showed that relapse occurred in 20% of patients under satralizumab treatment vs. 43% of the patients with placebo (hazard ratio, 0.38).
SUMMARY
Scientific evidence from case reports and series also . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.